We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

72 hedge funds and large institutions have $67.4M invested in Dianthus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $51.9M → $67.4M (+$15.5M)

0.46% more ownership

Funds ownership: 4.84% → 5.3% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 75 → 72 (-3)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

29% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 24

Holders
72
Holders Change
-3
Holders Change %
-4%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
17
Reduced
24
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$6.18M
2
RCM
RA Capital Management
Massachusetts
+$6.14M
3
WP
Woodline Partners
California
+$636K
4
Millennium Management
Millennium Management
New York
+$376K
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$193K

Top Sellers

1
CC
Casdin Capital
New York
-$3.58M
2
JP Morgan Chase
JP Morgan Chase
New York
-$787K
3
Renaissance Technologies
Renaissance Technologies
New York
-$559K
4
GPP
Great Point Partners
Connecticut
-$258K
5
Federated Hermes
Federated Hermes
Pennsylvania
-$227K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
51
Tower Research Capital (TRC)
New York
$18K +$821 +30 +4%
Balyasny Asset Management
52
Balyasny Asset Management
Illinois
$17K +$20.8K +761 New
LP
53
LMR Partners
United Kingdom
$15K – – –
RG
54
Rathbones Group
United Kingdom
$14K – – –
UBS Group
55
UBS Group
Switzerland
$12K +$14.2K +517 New
Barclays
56
Barclays
United Kingdom
$10K -$2.38K -87 -16%
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$8K +$1.83K +67 +25%
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$7.32K -$38.8K -1,416 -81%
JP Morgan Chase
59
JP Morgan Chase
New York
$4K -$787K -28,729 -99%
Rockefeller Capital Management
60
Rockefeller Capital Management
New York
$4K -$1.01K -37 -16%
O
61
OrbiMed
New York
$3.17K – – –
Wells Fargo
62
Wells Fargo
California
$3K -$5.75K -210 -60%
Simplex Trading
63
Simplex Trading
Illinois
$2K -$438 -16 -13%
Citigroup
64
Citigroup
New York
$1K -$821 -30 -41%
Fidelity Investments
65
Fidelity Investments
Massachusetts
$1K -$329 -12 -25%
UB
66
UMB Bank
Missouri
$1K – – –
AIM
67
Axiom Investment Management
New York
$1K +$849 +31 New
CUAMC
68
China Universal Asset Management Company
China
$1K +$931 +34 New
Federated Hermes
69
Federated Hermes
Pennsylvania
– -$227K -11,832 Closed
First Trust Advisors
70
First Trust Advisors
Illinois
– -$66K -3,455 Closed
D.E. Shaw & Co
71
D.E. Shaw & Co
New York
– -$64K -3,314 Closed
Susquehanna International Group
72
Susquehanna International Group
Pennsylvania
– -$55K -2,873 Closed
CM
73
Crestline Management
Texas
– -$31K -1,633 Closed
YIH
74
Y-Intercept (HK)
Hong Kong
– -$13K -672 Closed
CSS
75
Cubist Systematic Strategies
Connecticut
– -$13K -667 Closed
1 2
3
4

DNTH Hedge Fund Activity: Q3 2022 in Review

72 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2022, worth a combined $67.4M — up 30% from $51.9M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of DNTH and 8 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 17 added.

The largest buyer was Janus Henderson Group, adding an estimated $6.18M. The largest seller was Casdin Capital, cutting an estimated $3.58M.

  • 72 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2022, down from 75 in Q2 2022.
  • Funds reported $67.4M of Dianthus Therapeutics stock for Q3 2022, up 30% quarter-over-quarter.
  • 8 funds opened new Dianthus Therapeutics positions in Q3 2022 and 9 closed out, a net change of -1 holder.
  • The largest Dianthus Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $6.18M added.
  • The largest Dianthus Therapeutics seller in Q3 2022 was Casdin Capital, an estimated $3.58M sold.

Based on aggregated 13F filings for Q3 2022.